IASLC: Ivonescimab vs Pembrolizumab as First-Line Treatment in …
Sep 25, 2024 · In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC), according to Zhou et al.
Ivonescimab outperforms pembrolizumab in study for first-line …
Sep 8, 2024 · Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for...
Bispecific upstages Keytruda - Nature Biotechnology
Oct 14, 2024 · The new bispecific drug ivonescimab has outperformed Merck’s blockbuster PD-1 checkpoint inhibitor Keytruda (pembrolizumab) in a head-to-head clinical trial of non-small-cell lung cancer.
Ivonescimab Monotherapy Decisively Beats Pembrolizumab …
May 30, 2024 · HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1...
Summit therapy beat Merck blockbuster Keytruda in late-stage …
Sep 8, 2024 · The Summit drug, an antibody called ivonescimab, reduced the risk of tumor progression by 49% compared to Keytruda, according to data released here at the World Conference on Lung Cancer.
Akeso's Ivonescimab Head-to-Head Phase III Data Against …
Sep 8, 2024 · Ivonescimab as first-line treatment for PD-L1 positive NSCLC significantly extends median progression-free survival (mPFS) compared to pembrolizumab, with both statistical and clinical...
Ivonescimab Monotherapy Decisively Beats Pembrolizumab …
May 30, 2024 · Ivonescimab, known as AK112 is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis...
Two Ivonescimab (PD-1/VEGF) Results including Phase 3
Aug 14, 2024 · Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC. HONG KONG, August 10, 2024 -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced two upcoming oral presentations of ivonescimab (PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on ...
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in …
Sep 8, 2024 · Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.
Ivonescimab Monotherapy Reduced the Risk of Disease …
Sep 8, 2024 · Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC.